Division of Internal Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Division of Hematology & Oncology, Oregon Health & Science University, Portland, Oregon, USA.
Eur J Haematol. 2023 May;110(5):470-479. doi: 10.1111/ejh.13930. Epub 2023 Feb 12.
Intranasal, subcutaneous, or intravenous desmopressin can be utilized to release von Willebrand Factor and Factor VIII into circulation, enhance platelet adhesion and shorten bleeding time. Due to these properties, desmopressin can be effective in controlling bleeding in mild hemophilia A, certain subtypes of von Willebrand disease and in acute bleeding from uremia, end stage renal disease, and liver disease. Its use, however, can be complicated by hyponatremia and rarely arterial thrombotic events. While desmopressin has also been used as a prophylactic blood sparing agent in orthopedic, renal, and hepatic procedures, clinical studies have shown limited benefit in these settings. The purpose of this article is to review the evidence for desmopressin in primary hematologic disorders, discuss its mechanism of action and evaluate its utility as a hemostatic and blood sparing product in various bleeding conditions.
鼻腔内、皮下或静脉内给予去氨加压素可以将血管性血友病因子和因子 VIII 释放到循环中,增强血小板黏附并缩短出血时间。由于这些特性,去氨加压素可有效控制轻度血友病 A、某些类型的血管性血友病和尿毒症、终末期肾病和肝病急性出血。然而,其使用可能会导致低钠血症和罕见的动脉血栓事件。尽管去氨加压素也已被用作骨科、肾脏和肝脏手术中的预防性血液节约剂,但临床研究表明其在这些情况下的益处有限。本文的目的是回顾去氨加压素在原发性血液系统疾病中的证据,讨论其作用机制,并评估其在各种出血情况下作为止血和节约血液产品的效用。